These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34806812)

  • 1. Point-of-care hepatitis C testing and treatment strategy for people attending harm reduction and addiction centres for hepatitis C elimination.
    Forns X; Colom J; García-Retortillo M; Quer JC; Lens S; Martró E; Domínguez-Hernández R; Casado MÁ; Buti M
    J Viral Hepat; 2022 Mar; 29(3):227-230. PubMed ID: 34806812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analysis.
    Trickey A; Fajardo E; Alemu D; Artenie AA; Easterbrook P
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):253-270. PubMed ID: 36706775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Point-of-care hepatitis C screening with direct access referral to improve linkage to care among halfway house residents: a pilot randomised study.
    Hsiang JC; Sinnaswami P; Lee MY; Zhang MM; Quek KE; Tan KH; Wong YM; Thurairajah PH
    Singapore Med J; 2022 Feb; 63(2):86-92. PubMed ID: 32729280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study.
    Howell J; Traeger MW; Williams B; Layton C; Doyle JS; Latham N; Draper B; Bramwell F; Membrey D; McPherson M; Roney J; Stoové M; Thompson AJ; Hellard ME; Pedrana A
    J Viral Hepat; 2022 May; 29(5):375-384. PubMed ID: 35274403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C reinfection following successful direct-acting antiviral therapy among patients attending a multidisciplinary treatment centre for people who use drugs in Zurich, Switzerland.
    Falcato L; Bernardini C; Bruggmann P
    Int J Drug Policy; 2021 Oct; 96():103434. PubMed ID: 34511311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England.
    Hibbert M; Simmons R; Harris H; Desai M; Sabin CA; Mandal S
    J Viral Hepat; 2023 Aug; 30(8):646-655. PubMed ID: 36929670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of Hepatitis C and Addiction Treatment in People Who Inject Drugs: The San Patrignano HCV-Free and Drug-Free Experience.
    Piselli P; Boschini A; Gianfreda R; Nappo A; Cimaglia C; Scarfò G; Smacchia C; Paoletti R; Duehren S; Girardi E
    Viruses; 2024 Feb; 16(3):. PubMed ID: 38543741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eliminating hepatitis C on the Balearic Islands, Spain: a protocol for an intervention study to test and link people who use drugs to treatment and care.
    Lazarus JV; Herranz A; Picchio CA; Villota-Rivas M; Rodríguez A; Alonso JM; Moratinos A; Perrotta A; Tegeo E; Bibiloni F; Buti M; Vilella À
    BMJ Open; 2021 Oct; 11(10):e053394. PubMed ID: 34675021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of active hepatitis C in a single visit and linkage to care among marginalized people using a mobile unit in Madrid, Spain.
    Ryan P; Valencia J; Cuevas G; Torres-Macho J; Troya J; Pueyo Á; José Muñoz-Gómez M; Muñoz-Rivas N; Vázquez-Morón S; Martinez I; Lazarus JV; Resino S
    Int J Drug Policy; 2021 Oct; 96():103424. PubMed ID: 34429222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia.
    Saludes V; Antuori A; Folch C; González N; Ibáñez N; Majó X; Colom J; Matas L; Casabona J; Martró E;
    Int J Drug Policy; 2019 Dec; 74():236-245. PubMed ID: 31706159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada.
    Selfridge M; Cunningham EB; Barnett T; Drost A; Gray-Schleihauf C; Guarasci K; Lundgren K; Milne R; Grebely J; Fraser C
    Int J Drug Policy; 2021 Oct; 96():103418. PubMed ID: 34538704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries.
    Maticic M; Pirnat Z; Leicht A; Zimmermann R; Windelinck T; Jauffret-Roustide M; Duffell E; Tammi T; Schatz E
    Harm Reduct J; 2020 Nov; 17(1):89. PubMed ID: 33213481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
    Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
    J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
    Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
    AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reinfection with hepatitis C virus following sustained virological response in injection drug users.
    Grebely J; Knight E; Ngai T; Genoway KA; Raffa JD; Storms M; Gallagher L; Krajden M; Dore GJ; Duncan F; Conway B
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1281-4. PubMed ID: 20594256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era.
    Busschots D; Bielen R; Koc ÖM; Heyens L; Dercon E; Verrando R; Janssens F; Van den Bergh L; Van Lint P; Bruckers L; Nevens F; Robaeys G
    BMC Public Health; 2021 Aug; 21(1):1574. PubMed ID: 34416867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates.
    Lens S; Miralpeix A; Gálvez M; Martró E; González N; Rodríguez-Tajes S; Mariño Z; Saludes V; Reyes-Urueña J; Majó X; Colom J; Forns X
    JHEP Rep; 2022 Dec; 4(12):100580. PubMed ID: 36316992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peer-delivered point-of-care testing and linkage to treatment for hepatitis C virus infection among marginalized populations through a mobile clinic in Copenhagen, Denmark.
    Demant J; Krohn-Dehli L; Van der Veen J; Øvrehus A; Lazarus JV; Weis N
    Int J Drug Policy; 2023 Nov; 121():104185. PubMed ID: 37774576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
    Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
    Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.